

# Haemophilus influenzae Type B Infections (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/HA42FF17D45AEN.html>

Date: July 2021

Pages: 81

Price: US\$ 2,000.00 (Single User License)

ID: HA42FF17D45AEN

## Abstracts

Haemophilus influenzae Type B Infections (Infectious Disease) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Drugs In Development, 2021, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 9, 1, 9, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Haemophilus influenzae Type B Infections - Overview

Haemophilus influenzae Type B Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Haemophilus influenzae Type B Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development

AIM Vaccine Co Ltd

AVM Biotechnology LLC

Beijing Minhai Biotechnology Co Ltd

Biken Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

CanSino Biologics Inc

Changchun Heber Biotechnology Co Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Hilleman Laboratories Pvt Ltd

KM Biologics Co Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Novo Medi Sciences Pvt Ltd

Olymvax Biopharmaceuticals Inc

Orlance Inc

Panacea Biotec Ltd

Serum Institute of India Pvt Ltd

Shantha Biotechnics Pvt Ltd

Suzhou Weichao Biotechnology Co Ltd

Tuck-More Biotechnology Co Ltd

Vaxxilon AG

Wellstat Vaccines LLC

Yisheng Biopharma Co Ltd

Haemophilus influenzae Type B Infections - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis

(acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus)

(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis

(acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio +

tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis +

tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus)

(tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal

[serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine -

Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + tetanus + pertussis (acellular) + haemophilus influenzae [serotype B]) vaccine - Drug Profile

**Product Description****Mechanism Of Action****R&D Progress**

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

**Product Description**

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meningococcal [4-valent] + hemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

haemophilus influenza B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

haemophilus influenza B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action



R&D Progress

haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-Hib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae Type B Infections - Dormant Projects

Haemophilus influenzae Type B Infections - Discontinued Products

Haemophilus influenzae Type B Infections - Product Development Milestones

Featured News & Press Releases

Jan 07, 2019: Biomedical Sciences researcher gets \$3.26 million grant to develop universal flu vaccine

Jun 24, 2015: Hilleman Laboratories' preclinical trial report on Hib vaccine offers hope to millions of children

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Haemophilus influenzae Type B Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Haemophilus influenzae Type B Infections - Pipeline by AIM Vaccine Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by AVM Biotechnology LLC, 2021

Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Biken Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Biological E Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Cadila Healthcare Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by CanSino Biologics Inc, 2021

Haemophilus influenzae Type B Infections - Pipeline by Changchun Heber Biotechnology Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by GlaxoSmithKline Plc, 2021

Haemophilus influenzae Type B Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by KM Biologics Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Olymvax Biopharmaceuticals Inc, 2021

Haemophilus influenzae Type B Infections - Pipeline by Orance Inc, 2021

Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Shantha Biotechnics Pvt Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Tuck-More Biotechnology Co Ltd, 2021

Haemophilus influenzae Type B Infections - Pipeline by Vaxxilon AG, 2021

Haemophilus influenzae Type B Infections - Pipeline by Wellstat Vaccines LLC, 2021

Haemophilus influenzae Type B Infections - Pipeline by Yisheng Biopharma Co Ltd, 2021

Haemophilus influenzae Type B Infections - Dormant Projects, 2021

Haemophilus influenzae Type B Infections - Dormant Projects, 2021 (Contd..1)

Haemophilus influenzae Type B Infections - Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Haemophilus influenzae Type B Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Haemophilus influenzae Type B Infections (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/HA42FF17D45AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA42FF17D45AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

